Latest News-Ascentage Pharma Mediaroom_Page

Ascentage Pharma Announces Positive Data from Pivotal Phase II Studies of HQP1351 (Olverembatinib) in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) at 2020 American Society of Hematology (ASH) Annual Meeting

SUZHOU, China, and ROCKVILLE, MD, Dec. 8, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-12-08 08:16 2408

Ascentage Pharma Appoints Mr. Gang Zhu as Chief Commercial Officer to Lead Commercial Initiatives

SUZHOU, China and ROCKVILLE, Md., Dec. 4, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-12-04 08:28 2676

Ascentage Pharma Announces Clearances in China and the US for the Phase IIa Study of APG-115 Single Agent or in Combination with APG-2575 for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia

SUZHOU, China and ROCKVILLE, Md., Dec. 2, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-12-02 08:09 2631

Ascentage Pharma Enters into an Agreement with University of Michigan to obtain an exclusive license for a MDM2 Degrader using PROTAC Technology

SUZHOU, China and ROCKVILLE, Md., Nov. 30, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2020-11-30 08:09 2645

Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

SUZHOU, China and ROCKVILLE, Md., Nov. 25, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-11-25 08:27 2312

Ascentage Pharma Receives Approvals for Two Phase Ib/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenström Macroglobulinemia and Multiple Myeloma in China

SUZHOU, China and ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-11-23 18:32 1877

Ascentage Pharma to Release Updated Clinical Results of HQP1351 (Olverembatinib) in Drug-Resistant Chronic Myeloid Leukemia in an Oral Presentation at the American Society of Hematology Annual Meeting

SUZHOU, China and ROCKVILLE, Md., Nov. 9, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-11-09 08:04 2232

Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of MDM2-p53 Inhibitor APG-115 in Combination with Immunotherapy for the Treatment of Patients with Advanced Liposarcoma or other Advanced Solid Tumors in China

SUZHOU, China and ROCKVILLE, Md., Oct. 27, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-10-27 08:13 2376

Priority Review Granted to Ascentage Pharma's New Drug Application for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China

SUZHOU, China and ROCKVILLE, Md., Oct. 21, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-10-21 17:37 2286

Ascentage Pharma's Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations by the US FDA

SUZHOU, China and ROCKVILLE, MD., Oct. 9, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-10-09 08:21 3045

Ascentage Pharma's MDM2-p53 Inhibitor APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer

SUZHOU, China and ROCKVILLE, Md., Sept. 14, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2020-09-14 18:35 2171

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia

SUZHOU, China and ROCKVILLE, Md., Sept. 7, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-09-07 17:16 2616

Ascentage Pharma Releases Preclinical Results of IAP Antagonist APG-1387 in an Oral Presentation at EASL ILC 2020

SUZHOU, China and ROCKVILLE, Md., Aug. 27, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-08-27 18:10 5016

Ascentage Pharma Releases 2020 Interim Results, Reporting the Company's First New Drug Application and Advances in Global Strategic Collaborations

SUZHOU, China and ROCKVILLE, Md., Aug. 18, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-08-18 20:24 3782

Ascentage Pharma Releases 2020 Interim Results, Reporting the Company's First New Drug Application and Advances in Global Strategic Collaborations

Ascentage Pharma Becomes a Constituent of Three Major Indexes Including Hang Seng Composite Index

SUZHOU, China, and ROCKVILLE, MD., Aug. 17, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2020-08-17 07:30 3149

Ascentage Pharma Announces First Patient Dosed in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 as Single Agent and in Combinations for the Treatment of Hematologic Malignancies in China

SUZHOU, China and ROCKVILLE, Md., July 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-07-22 17:31 2247

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenström Macroglobulinemia

SUZHOU, China and ROCKVILLE, Md., July 15, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-07-15 21:07 2214

Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

SUZHOU, China, and ROCKVILLE, Md., July 6, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-07-06 13:00 2156

Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors

SUZHOU, China and ROCKVILLE, Md., June 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-06-22 07:15 2943

Ascentage Pharma Submits Its First New Drug Application to National Medical Products Administration, for HQP1351, the First Third-Generation BCR-ABL Inhibitor in China

SUZHOU, China and ROCKVILLE, Md., June 18, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-06-18 17:30 2222